Check-Cap Featured at the World Endoscopy Organization Colorectal Cancer Screening Committee Meeting

News provided by

Oct 26, 2015, 07:00 ET

ISFIYA, Israel, Oct. 26, 2015 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that the Check-Cap system was highlighted at the World Endoscopy Organization Colorectal Cancer Screening Committee (WEO CRC SC) Meeting which took place on October 23 in Barcelona, Spain.

Prof. Nadir Arber, M.D., Director, Integrated Cancer Prevention Center at the Tel Aviv Sourasky Medical Center in Israel, and a scientific advisor to Check-Cap, presented an overview of the Check-Cap System in a special session devoted to new techniques in colorectal cancer screening.

"Colorectal cancer represents a significant public health issue, with global treatment costs estimated at approximately $100 billion. Although highly preventable with routine screening, studies suggest that fewer than two-thirds of individuals aged 50-75 adhere to current screening recommendations. This year's WEO CRC SC Meeting demonstrated that the medical device industry is collectively focused on exploring and learning about alternative screening modalities, including the Check-Cap system, as a means of increasing adherence with CRC screening guidelines," said Dr. Arber.

The WEO CRC SC was founded nearly 20 years ago as a forum for international professional interaction in the area of colorectal cancer. It promotes innovation and effective practices in the screening and surveillance of CRC. This year's committee meeting had more than 150 leading physicians and industry experts in attendance. The meeting took place the day before the official start of the United European Gastroenterology (UEG) Week, where Prof. Arber will also be presenting a poster demonstrating safety and detection of polyps in clinical tests evaluating the Check-Cap system.

About Check-Cap

Check-Cap is a clinical stage medical diagnostics company developing the first non-invasive system for preparation-free imaging of the colon to identify precancerous polyps and cancers. The Company is developing an ingestible capsule that utilizes proprietary, ultra-low-energy X-ray-based technology to safely generate high-resolution, 3-dimensional imagery of the interior of the colon. Without requiring traditional bowel cleansing or diet and activity modifications, Check-Cap's system is designed to increase patient acceptance and adherence to colorectal cancer screening recommendations. The Check-Cap system is currently not cleared for marketing in any jurisdiction.

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

CONTACT:
Investors
David Carey
Lazar Partners Ltd.
212-867-1768
[email protected]

Vivian Cervantes
PCG Advisory Group
212-554-5482
[email protected]

Media
Erich Sandoval
Lazar Partners Ltd.
917-497-2867
[email protected]

SOURCE Check-Cap Ltd.